25 May 2013
Keywords: oncologists, reluctant, switch, tykerb, yet, ready, use
Article | 20 August 2007
Oncologists are "not yet ready" to use UK drug major GlaxoSmithKline's Tykerb (lapatinib), an oral dual kinase inhibitor therapy, as ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 August 2007
24 May 2013
© 2013 thepharmaletter.com